Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. a meta-analysis of published studies;Efecto del alendronato sobre la densidad mineral ósea y la incidencia de fracturas en mujeres posmenopáusicas con osteoporosis. Un metaanálisis de los estudios publicados

Medicina Clinica

Volumn 114, Issue SUPPL. 2, 2000, Pages 79-84

  Arboleya, Luis R ^a   Morales, Antonio ^b   Fiter, Jordi ^c  

^a HOSPITAL DE CABUEÑES   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Alendronate; Fractures; Meta analysis; Osteoporosis; Postmenopausal; Randomized controlled trial

Indexed keywords

ALENDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MINERALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; HIP FRACTURE; HUMAN; META ANALYSIS; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL;

ALENDRONATE; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0033660536     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. NIH Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-650.
2. Arboleya LR, Castro MA, Bartolomé R, Gervás L, Vega R. Epidemiología de la fractura osteoporótica de cadera en la provincia de Palencia. Rev Clin Esp 1997; 197: 611-617.
3. Arboleya LR. Osteoporosis en la mujer postmenopáusica. Rev Esp Farmacoecon 1998; 4: 21-25.
4. Pols HA, Felsenberg D, Hanley DA, Stepan J, Muñoz-Torres M, Wilkin TJ et al. A multinational randomized trial of the effects of alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Osteoporosis Int 1999; 9: 461-468.
5. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
6. Juni P, Witschi A, Black R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 1054-1060.
7. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trial 1986; 7: 177-188.
8. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Mine Res 1998; 13: 1431-1438.
9. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double blind, randomized, controlled trial. Ann Intern Med 1998; 128: 253-261.
10. Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485-492.
11. Frediani B, Allegri A, Bisogno S, Marcolongo R. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous treatment. Clin Drug Invest 1998; 15: 236-244.
12. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H et al. A placebo-controlled, single blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocrine J 1998; 45: 191-201.
13. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383-390.
14. Chesnut CH, McClung MR, Ensrud KE, Bell NL, Genant H, Harris ST et al. Alendronate treatment of the postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-152.
15. Liberman UA, Weiss SR, Broll J, Minne HW, Hui Q, Bell N et al. Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.
16. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
17. Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein R, Licata AA et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997; 82: 265-274.
18. Cummings SR, Black DM, Thompson D, Applegate WB, Barret-Connor E, Musliner T et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. JAMA 1998; 280: 2077-2082.
19. Meunier PJ. Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomized clinical trials. Int J Clin Pract 1999; 53: 122-129.
20. Rodan GA. Bone mass homeostasis and bisphosphonate action. Bone 1997; 20: 1-4.
21. Karpf DB, Shapiro DR, Seeman E, Ensrud K, Johnston CC, Admans S et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 1997; 277: 1159-1164.
22. Cranney A, Welch V, Coyle D, Adachi J, Tugwell P, Wells G et al. Cochrane review of alendronate for prevention and treatment of postmenopausal osteoporosis. Arthritis Rheum 1998; 41 (Supl 9): 608.